These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37469246)

  • 141. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
    J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
    [TBL] [Abstract][Full Text] [Related]  

  • 142. Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.
    Imai H; Wasamoto S; Tsuda T; Nagai Y; Kishikawa T; Masubuchi K; Osaki T; Miura Y; Umeda Y; Ono A; Minemura H; Yamada Y; Nakagawa J; Kozu Y; Taniguchi H; Ohta H; Kasai T; Kaira K; Kagamu H
    Thorac Cancer; 2023 Sep; 14(25):2567-2578. PubMed ID: 37469246
    [TBL] [Abstract][Full Text] [Related]  

  • 143. Efficacy and Safety of First-line Pembrolizumab Plus Platinum and Pemetrexed in Elderly Patients with Non-squamous Non-small-cell Lung Cancer.
    Wasamoto S; Imai H; Tsuda T; Nagai Y; Kishikawa T; Ono A; Masubuchi K; Umeda Y; Yamada Y; Nakagawa J; Yui T; Taniguchi H; Kaira K; Kagamu H
    Intern Med; 2024 May; ():. PubMed ID: 38749728
    [TBL] [Abstract][Full Text] [Related]  

  • 144. Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.
    Nishihara-Kato F; Imai H; Tsuda T; Wasamoto S; Nagai Y; Kishikawa T; Miura Y; Ono A; Yamada Y; Masubuchi K; Osaki T; Nakagawa J; Umeda Y; Minemura H; Kozu Y; Taniguchi H; Ohta H; Kaira K; Kagamu H
    Oncology; 2024; 102(1):30-42. PubMed ID: 37598676
    [TBL] [Abstract][Full Text] [Related]  

  • 145. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
    Wang J; Liu Y; Mi X; Shao M; Liu L
    Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
    [TBL] [Abstract][Full Text] [Related]  

  • 146. Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With Pembrolizumab.
    Romano FJ; Ronga R; Ambrosio F; Arundine D; Longo V; Galetta D; Gridelli C; Maione P; Palma V; Damiano V; Verde A; Giacobbe I; Augurio MR; Iengo G; Chetta M; Tarsitano M; Campione S; Failla G; Raucci A; Riccardi F
    Cancer Diagn Progn; 2023; 3(1):44-52. PubMed ID: 36632583
    [TBL] [Abstract][Full Text] [Related]  

  • 147. The association of body mass index with safety and effectiveness of first-line carboplatin-based chemotherapy in patients with metastatic non-small cell lung cancer.
    Kicken MP; Kilinc HD; Cramer-van der Welle CM; Houterman S; van den Borne BEEM; Smit AAJ; van de Garde EMW; Deenen MJ;
    Cancer Treat Res Commun; 2023; 34():100676. PubMed ID: 36592497
    [TBL] [Abstract][Full Text] [Related]  

  • 148. Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review.
    Guo Y; Xiang D; Wan J; Yang L; Zheng C
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358716
    [TBL] [Abstract][Full Text] [Related]  

  • 149. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Markers for Advanced Non-Small-Cell Lung Cancer Treated with Immunotherapy: A Systematic Review and Meta-Analysis.
    Platini H; Ferdinand E; Kohar K; Prayogo SA; Amirah S; Komariah M; Maulana S
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013536
    [TBL] [Abstract][Full Text] [Related]  

  • 150. Cancer statistics, 2022.
    Siegel RL; Miller KD; Fuchs HE; Jemal A
    CA Cancer J Clin; 2022 Jan; 72(1):7-33. PubMed ID: 35020204
    [TBL] [Abstract][Full Text] [Related]  

  • 151. Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancer.
    Tateishi A; Horinouchi H; Yoshida T; Masuda K; Jo H; Shinno Y; Okuma Y; Goto Y; Yamamoto N; Ohe Y
    Respir Investig; 2022 Mar; 60(2):234-240. PubMed ID: 34972681
    [TBL] [Abstract][Full Text] [Related]  

  • 152. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
    Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
    Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
    [TBL] [Abstract][Full Text] [Related]  

  • 153. Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
    Velcheti V; Hu X; Piperdi B; Burke T
    Sci Rep; 2021 Apr; 11(1):9222. PubMed ID: 33911121
    [TBL] [Abstract][Full Text] [Related]  

  • 154. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab.
    Ksienski D; Wai ES; Alex D; Croteau NS; Freeman AT; Chan A; Patterson T; Clarkson M; Fiorino L; Poonja Z; Fenton D; Irons S; Lesperance M
    Transl Lung Cancer Res; 2021 Jan; 10(1):355-367. PubMed ID: 33569318
    [TBL] [Abstract][Full Text] [Related]  

  • 155. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
    Paz-Ares L; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Salman P; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; John T; Carbone DP; Meadows-Shropshire S; Agrawal S; Oukessou A; Yan J; Reck M
    Lancet Oncol; 2021 Feb; 22(2):198-211. PubMed ID: 33476593
    [TBL] [Abstract][Full Text] [Related]  

  • 156. Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Takamori S; Takada K; Shimokawa M; Matsubara T; Fujishita T; Ito K; Toyozawa R; Yamaguchi M; Okamoto T; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
    Lung Cancer; 2021 Feb; 152():27-33. PubMed ID: 33341085
    [TBL] [Abstract][Full Text] [Related]  

  • 157. Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients.
    Katayama Y; Yamada T; Chihara Y; Tanaka S; Tanimura K; Okura N; Hirose K; Uda S; Shiotsu S; Hirai S; Hiranuma O; Harada T; Shimamoto T; Iwasaku M; Kaneko Y; Uchino J; Takeda T; Takayama K
    Sci Rep; 2020 Oct; 10(1):17495. PubMed ID: 33060826
    [TBL] [Abstract][Full Text] [Related]  

  • 158.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 159.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 160.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.